Financials Qingdao Haier Biomedical Co.,Ltd

Equities

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
36.93 ^CNY	+7.17%		+12.59%	-8.86%

Apr. 25	Qingdao Haier Biomedical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 02	Tranche Update on Qingdao Haier Biomedical Co.,Ltd's Equity Buyback Plan announced on February 9, 2024.	CI

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	9,157	20,702	28,796	20,078	12,824	11,658	-	-
Enterprise Value (EV) ¹	9,157	20,702	28,796	20,078	12,824	11,658	11,658	11,658
P/E ratio	39.6 x	54.4 x	34.1 x	33.5 x	31.7 x	23.2 x	15.8 x	15.3 x
Yield	-	-	-	-	-	-	-	-
Capitalization / Revenue	9.04 x	14.8 x	13.5 x	7.01 x	5.62 x	4.19 x	3.17 x	2.9 x
EV / Revenue	9.04 x	14.8 x	13.5 x	7.01 x	5.62 x	4.19 x	3.17 x	2.9 x
EV / EBITDA	-	45.9 x	28.5 x	27.2 x	23.9 x	18.9 x	15.4 x	12.7 x
EV / FCF	-	-	-	-	-	-	-	-
FCF Yield	-	-	-	-	-	-	-	-
Price to Book	-	7.46 x	8.01 x	5.01 x	3.05 x	2.54 x	2.28 x	2.03 x
Nbr of stocks (in thousands)	317,072	317,072	317,072	317,193	316,493	315,683	-	-
Reference price ²	28.88	65.29	90.82	63.30	40.52	36.93	36.93	36.93
Announcement Date	3/26/20	2/22/21	2/16/22	2/27/23	2/26/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	1,013	1,402	2,126	2,864	2,281	2,784	3,678	4,019
EBITDA ¹	-	450.7	1,011	738	536.8	616.2	754.8	917.6
EBIT ¹	-	427.5	961.4	675.7	438.4	560.4	694.8	855.4
Operating Margin	-	30.49%	45.23%	23.59%	19.22%	20.13%	18.89%	21.29%
Earnings before Tax (EBT) ¹	-	424.2	960.9	675.3	434.5	558.7	835.1	853.7
Net income ¹	-	381	845	600.8	406.1	505.9	744.3	769.6
Net margin	-	27.17%	39.75%	20.98%	17.8%	18.17%	20.24%	19.15%
EPS ²	0.7300	1.200	2.660	1.890	1.280	1.593	2.342	2.420
Free Cash Flow	-	-	-	-	-	-	-	-
FCF margin	-	-	-	-	-	-	-	-
FCF Conversion (EBITDA)	-	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-	-
Dividend per Share	-	-	-	-	-	-	-	-
Announcement Date	3/26/20	2/22/21	2/16/22	2/27/23	2/26/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow	-	-	-	-	-	-	-	-
ROE (net income / shareholders' equity)	-	14.6%	26%	15.9%	9.91%	11%	12.2%	13.3%
ROA (Net income/ Total Assets)	-	-	-	11.6%	7.37%	7.9%	9%	9.7%
Assets ¹	-	-	-	5,194	5,510	6,403	8,270	7,934
Book Value Per Share ²	-	8.750	11.30	12.60	13.30	14.50	16.20	18.20
Cash Flow per Share ²	-	2.200	1.870	1.990	0.7800	1.650	2.200	2.700
Capex ¹	-	-	-	294	176	340	370	380
Capex / Sales	-	-	-	10.27%	7.71%	12.21%	10.06%	9.46%
Announcement Date	3/26/20	2/22/21	2/16/22	2/27/23	2/26/24	-	-	-

¹CNY in Million²CNY

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

36.93 CNY

Average target price

57.5 CNY

Spread / Average Target

+55.70%

	1st Jan change	Capi.
QINGDAO HAIER BIOMEDICAL CO.,LTD	-8.86%	1.61B
THERMO FISHER SCIENTIFIC	+8.07%	219B
DANAHER CORPORATION	+6.59%	183B
INTUITIVE SURGICAL, INC.	+11.26%	133B
BOSTON SCIENTIFIC CORPORATION	+26.57%	108B
EDWARDS LIFESCIENCES CORPORATION	+13.35%	52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.62%	48.2B
AGILENT TECHNOLOGIES, INC.	-0.93%	40.37B
GE HEALTHCARE TECHNOLOGIES INC.	+11.54%	39.35B
RESMED, INC.	+26.76%	32.03B